

Feng-Chun Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1688713/publications.pdf>

Version: 2024-02-01

33
papers

1,823
citations

304743

22
h-index

414414

32
g-index

33
all docs

33
docs citations

33
times ranked

3218
citing authors

#	ARTICLE	IF	CITATIONS
1	Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. <i>Blood</i> , 2011, 118, 4509-4518.	1.4	562
2	Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. <i>Blood</i> , 2014, 123, 541-553.	1.4	145
3	Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. <i>Blood</i> , 2018, 131, 328-341.	1.4	133
4	HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice. <i>Cancer Cell</i> , 2019, 36, 645-659.e8.	16.8	116
5	Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. <i>Nature Communications</i> , 2017, 8, 15102.	12.8	88
6	Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1065-1077.	2.5	74
7	A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies. <i>Leukemia</i> , 2018, 32, 1327-1337.	7.2	50
8	CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. <i>Cancer Cell</i> , 2018, 33, 1111-1127.e5.	16.8	48
9	HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia. <i>Molecular Cell</i> , 2022, 82, 833-851.e11.	9.7	48
10	Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner. <i>Blood</i> , 2017, 129, 2782-2792.	1.4	39
11	ASXL1 plays an important role in erythropoiesis. <i>Scientific Reports</i> , 2016, 6, 28789.	3.3	38
12	Cardiac Sca-1 ⁺ Cells Are Not Intrinsic Stem Cells for Myocardial Development, Renewal, and Repair. <i>Circulation</i> , 2018, 138, 2919-2930.	1.6	37
13	ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis. <i>Science Advances</i> , 2017, 3, e1601602.	10.3	35
14	TET2 Loss Dysregulates the Behavior of Bone Marrow Mesenchymal Stromal Cells and Accelerates Tet2-Driven Myeloid Malignancy Progression. <i>Stem Cell Reports</i> , 2018, 10, 166-179.	4.8	34
15	Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia. <i>Stem Cell Investigation</i> , 2017, 4, 48-48.	3.0	31
16	Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells. <i>Current Opinion in Hematology</i> , 2010, 17, 287-293.	2.5	29
17	Upregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion. <i>Oncotarget</i> , 2016, 7, 78095-78109.	1.8	29
18	Loss of ASXL1 in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates. <i>Cell Discovery</i> , 2018, 4, 4.	6.7	28

#	ARTICLE	IF	CITATIONS
19	HOXB13 long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 1956.	12.8	28
20	The <sc>TET2</sc> interactors and their links to hematological malignancies. <i>IUBMB Life</i> , 2015, 67, 438-445.	3.4	27
21	ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis. <i>Leukemia</i> , 2019, 33, 1287-1291.	7.2	26
22	Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy. <i>Journal of Clinical Investigation</i> , 2018, 128, 5383-5398.	8.2	25
23	The catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function in hematopoietic stem/progenitor cells. <i>Leukemia</i> , 2016, 30, 1784-1788.	7.2	24
24	Loss of Asxl2 leads to myeloid malignancies in mice. <i>Nature Communications</i> , 2017, 8, 15456.	12.8	23
25	Tet2 Regulates Osteoclast Differentiation by Interacting with Runx1 and Maintaining Genomic 5-Hydroxymethylcytosine (5hmC). <i>Genomics, Proteomics and Bioinformatics</i> , 2018, 16, 172-186.	6.9	22
26	Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo. <i>Leukemia</i> , 2018, 32, 1834-1837.	7.2	20
27	Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cells, Leading to Bohring-Opitz-like Syndrome in Mice. <i>Stem Cell Reports</i> , 2016, 6, 914-925.	4.8	18
28	Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin. <i>Blood</i> , 2016, 127, 2322-2326.	1.4	15
29	p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia. <i>JCI Insight</i> , 2021, 6, .	5.0	11
30	Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism. <i>Endocrinology</i> , 2017, 158, 2722-2740.	2.8	9
31	INTS11 regulates hematopoiesis by promoting PRC2 function. <i>Science Advances</i> , 2021, 7, eabh1684.	10.3	6
32	The Role of ASXL1/2 and Their Associated Proteins in Malignant Hematopoiesis. <i>Current Stem Cell Reports</i> , 2020, 6, 6-15.	1.6	5
33	Suv39h1 Represses the Progression of MLL-Rearranged Myeloid Leukemia Via Hoxb13. <i>Blood</i> , 2018, 132, 3878-3878.	1.4	0